Item 2.02 Results of Operations and Financial Condition. On February 24, 2026, Iovance Biotherapeutics, Inc. (the “ Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.

Item 8.01 Other Events. On February 24, 2026, the Company updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company's presentation that it intends to use at such events is attached as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. 99.1 Press Release of Iovance Biotherapeutics, Inc., dated February 24, 2026. ───────────────────────────────────────────────────────────────────────────────────────── 99.2 Iovance Biotherapeutics, Inc., Corporate Presentation - February 2026. 104 Cover Page Interactive Data File (embedded as Inline XBRL document) SIGNATURES